Integrated Platform of siRNA Drug Discovery
RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality. To accelerate the discovery of novel siRNAs, WuXi AppTec has established an integrated platform encompassing siRNA sequence design, chemical synthesis/modification, delivery ligand exploration, and activity/off-target assessment.
At the TIDES USA 2024 Conference, our scientists presented a poster showcasing the effectiveness of this platform in conducting a comprehensive study on complement component 5 (C5) siRNAs, identifying chemically modified C5-targeting siRNAs that exhibit potent inhibition of C5 mRNA with minimal off-target effects.
TIDES USA Poster_Integrated Platform of siRNA Drug Discovery
Related Content
Psoriasis is a chronic autoimmune skin disease characterized by abnormal keratinocyte proliferation and infiltration of inflammatory cells. The absence of...
VIEW RESOURCEVitiligo is an autoimmune disorder characterized by the progressive destruction of melanocytes in the skin. This condition is driven by...
VIEW RESOURCE